Information Provided By:
Fly News Breaks for April 25, 2019
KALA
Apr 25, 2019 | 09:10 EDT
As previously reported, Oppenheimer analyst Esther Rajavelu started coverage of Kala Pharmaceuticals with an Outperform rating and $11 price target. With strong initial uptake of Inveltys, and KPI-121 regulatory catalyst in Q3, the analyst believes Kala Pharmaceuticals is well positioned for top line growth. His channel checks with ocular surgeons support Inveltys prescription growth over the next twelve months. Separately, he believes KPI-121 may address a significant unmet need in the nascent dry eye disease market.
News For KALA From the Last 2 Days
There are no results for your query KALA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.